We would love to hear your thoughts about our site and services, please take our survey here.
Just need a RNS to say that they are out and the SP will rise.
FOMO? I'm still not sure, why it's gone up a bit this morning.
Possible, there was an uptick from 5% down to 2% down. But then there's probably at least £100k of big sales this morning too. So yeah, very odd trading patterns today.
Something just doesn't sit right with me. Not too sure what's going on, but the chunky sells from earlier doesn't inspire confidence. IMHO.
Can't work out if these are big sells or buys?
12:12:42 1.2738 5,102,136 64.99k O
12:09:25 1.2501 800,255 10.00k O
12:05:54 1.2555 3,982,795 50.00k
any ideas? Thanks
I agree, it will hopefully slowly climb over the next few days and gain momentum. It's only this low due to profit takers from this morning.
I guess that this is a worry that them cashing in would drop the SP, how many do they have?
But on a positive note, once they have blown through it, there won't be any further RF restrictions.
You can only buy in small numbers, there just isn't stock unless someone dumps a load.
...It's the conservative British way :)
I suspect a massive exodus, because of the sell price. But once PEEL is done, it will go back up.
Glad I got in last night, already up on paper.
This is surely going to go nuts today?
NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR.
Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.
ANGLE's DDR assay has the potential to be used as a repeatable, minimally invasive means to better understand the DDR pathway to enable development of therapies capable of targeting tumour-specific DDR dependencies to preferentially kill cancer cells. The assay may also have the potential for monitoring treatment response to DDR therapies administered in combination with other cancer drugs.
ANGLE Chief Executive Officer, Andrew Newland, commented:
"This is ANGLE's second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business. It demonstrates the importance of CTC analysis and is a validation of ANGLE's Parsortix system. ANGLE is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity."
ANGLE Chief Scientific Officer, Karen Miller commented:
"We are delighted that our expertise in CTC assay development continues to make great strides. With the increasing investigation of DNA damage response / PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers."
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells. Treating patients with a DDR inhibitor alongside another cancer d
I'm guessing it won't drop back to 10p or 20p because of the latest RNS, indicating that RF are now out?
Thank you for the link. Very useful.
HE1 was a laugh. I bought back into it at 0.060 and watch it hit 3p when I bailed.
Only wished I had more funds to buy in at that low SP. Two days of 100% SP increase and the a following day of cooling down. It will go again when it gets closer to Q3.
As you say, SAR feels the same I'm hoping that with RF gone, investors will want to load up whilst it's still under 50p.
Although I didn't catch this at 10p, I do think it has the legs to run up to 75p and over £1 on new news.
No UT yet, so there may be some adjustment to the SP before tomorrow, in a positive way.
Should hopefully see 35-40p tomorrow.
Could be FOMO, but this will open tomorrow and traders will want to get in ASAP for another 10%+ increase in SP. So, get in now whilst it's cheaper than tomorrow's open.
I had to break the buys down into 8 to get a buy price. Just spent over £88 in transaction fees! The buggers. But i'm in now.
It will be higher if i could buy more. I'm stuck with NT at the moment on HL, unless i buy 2 shares. Will just need to wait until it ticks up to PEEL i suppose.